These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 20333869)

  • 1. Relationships between osteoprotegerin (OPG), receptor activator of nuclear factor kappaB ligand (RANKL), and growth hormone (GH) secretory status in short children.
    Flint J; Wu S; Shott S; Suarez E; De Luca F
    J Pediatr Endocrinol Metab; 2009 Dec; 22(12):1105-12. PubMed ID: 20333869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoprotegerin, Receptor Activator of Nuclear Factor Kappa B Ligand, and Growth Hormone/Insulin-Like Growth Factor-1 Axis in Children with Growth Hormone Deficiency.
    Witkowska-Sędek E; Rumińska M; Stelmaszczyk-Emmel A; Sobol M; Demkow U; Pyrżak B
    Adv Exp Med Biol; 2018; 1116():63-73. PubMed ID: 30284692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women.
    Zhao HY; Liu JM; Ning G; Zhao YJ; Chen Y; Sun LH; Zhang LZ; Xu MY; Chen JL
    Osteoporos Int; 2008 Feb; 19(2):221-6. PubMed ID: 17703270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
    Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
    Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum RANKL, osteoprotegerin (OPG) and RANKL/OPG ratio in children with systemic lupus erythematosus.
    Ali R; Hammad A; El-Nahrery E; Hamdy N; Elhawary AK; Eid R
    Lupus; 2019 Sep; 28(10):1233-1242. PubMed ID: 31403902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo.
    Rubin J; Ackert-Bicknell CL; Zhu L; Fan X; Murphy TC; Nanes MS; Marcus R; Holloway L; Beamer WG; Rosen CJ
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4273-9. PubMed ID: 12213884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum osteoprotegrin (OPG) and receptor activator of nuclear factor kappaB (RANKL) in healthy children and adolescents.
    Wasilewska A; Rybi-Szuminska AA; Zoch-Zwierz W
    J Pediatr Endocrinol Metab; 2009 Dec; 22(12):1099-104. PubMed ID: 20333868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OPG/RANK/RANKL signaling axis in patients with type I diabetes: Associations with parathormone and vitamin D.
    Karalazou P; Ntelios D; Chatzopoulou F; Fragou A; Taousani M; Mouzaki K; Galli-Tsinopoulou A; Kouidou S; Tzimagiorgis G
    Ital J Pediatr; 2019 Dec; 45(1):161. PubMed ID: 31823791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis.
    Ozkaya O; Buyan N; Bideci A; Gonen S; Ortac E; Fidan K; Cinaz P; Söylemezoğlu O
    Nephron Clin Pract; 2007; 105(4):c153-8. PubMed ID: 17259742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between serum levels of estradiol and osteoprotegerin in patients with anorexia nervosa.
    Ohwada R; Hotta M; Sato K; Shibasaki T; Takano K
    Endocr J; 2007 Dec; 54(6):953-9. PubMed ID: 17998762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationships between OPG, RANKL, bone metabolism, and bone mineral density in biliary atresia.
    Honsawek S; Chaiwatanarat T; Vejchapipat P; Chongsrisawat V; Thawornsuk N; Poovorawan Y
    Pediatr Surg Int; 2009 Mar; 25(3):261-7. PubMed ID: 19184056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
    Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation of RANKL and OPG Levels with Bone Resorption in Patients with Acromegaly and Prolactinoma.
    Ozer FF; Dagdelen S; Erbas T
    Horm Metab Res; 2018 Jul; 50(7):562-567. PubMed ID: 29895074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: are they of any help?
    Wagner D; Fahrleitner-Pammer A
    Wien Med Wochenschr; 2010 Sep; 160(17-18):452-7. PubMed ID: 20714810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?
    Kananen K; Volin L; Laitinen K; Ruutu T; Välimäki MJ
    Osteoporos Int; 2006; 17(5):724-30. PubMed ID: 16437190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study.
    Stern A; Laughlin GA; Bergstrom J; Barrett-Connor E
    Eur J Endocrinol; 2007 May; 156(5):555-62. PubMed ID: 17468191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
    Shaarawy M; Fathy SA; Mehany NL; Hindy OW
    Clin Chem Lab Med; 2007; 45(11):1498-503. PubMed ID: 17970704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imbalance of the osteoprotegerin/RANKL ratio in bone marrow microenvironment after allogeneic hemopoietic stem cell transplantation.
    Ricci P; Tauchmanova L; Risitano AM; Carella C; Mazziotti G; Lombardi G; Colao A; Rotoli B; Selleri C
    Transplantation; 2006 Dec; 82(11):1449-56. PubMed ID: 17164716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis.
    Rouster-Stevens KA; Langman CB; Price HE; Seshadri R; Shore RM; Abbott K; Pachman LM
    Arthritis Rheum; 2007 Mar; 56(3):977-83. PubMed ID: 17328075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
    Reyes-García R; Muñoz-Torres M; García DF; Mezquita-Raya P; García Salcedo JA; de Dios Luna J
    Menopause; 2010; 17(1):140-4. PubMed ID: 19574937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.